H.C. Wainwright Believes Antares Pharma (NASDAQ: ATRS) Won’t Stop Here

By Ryan Adsit

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Antares Pharma (ATRSResearch Report) today and set a price target of $4.50. The company’s shares closed yesterday at $3.61, close to its 52-week high of $3.93.

Livnat said:

“Our $4.50 12-month target is based on a sum-of-the-parts after comprising $1.9/share for the other base-business, $0.7/share for other unapproved partnered pipeline, plus $0.3/share NOL’s, less $1.2/share un-allocated OPEX. above components is based on projected individual operating profits, after tax (at 25%), discounted back to 12-months from now at a 10.5% discount rate. We assume a fully-diluted share count of nearly 167M shares.”

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 7.1% and a 57.6% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Jazz Pharmaceuticals, and Agile Therapeutics.

Antares Pharma has an analyst consensus of Strong Buy, with a price target consensus of $5.45, implying a 51.0% upside from current levels. In a report released yesterday, Jefferies also maintained a Buy rating on the stock with a $8 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $3.93 and a one-year low of $1.58. Currently, Antares Pharma has an average volume of 1.82M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Antares Pharma, Inc. is a pharmaceutical company. The company focuses on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. Its activities include the development of injection devices and injection based pharmaceutical products as well as transdermal gel products.